1 Department of Nursing and Physiotherapy, University of Cádiz, Cádiz, Spain.
2 Institute of Research and Innovation in Biomedical Sciences of the Province of Cádiz (INiBICA), University of Cádiz, Cádiz, Spain.
Integr Cancer Ther. 2019 Jan-Dec;18:1534735419846401. doi: 10.1177/1534735419846401.
The prevalence of cancer has increased over time worldwide. Nevertheless, the number of deaths has been reduced during the past 2 decades. Thus, one-third of the cancer patients are users of complementary and alternative therapies, looking for other types of interventions. The main aim of the present study is to understand the current status of the research in integrative and complementary oncology. Three different aspects were analyzed: production trends, country collaboration, and leading research topics.
The dataset was obtained from the documents indexed under the Integrative and Complementary Medicine category of the Web of Science database from 1976 to 2017. VOSviewer and SciMAT software were employed to perform the bibliometric analysis.
The Journal of Ethnopharmacology, China Medical University and the People's Republic of China are the leading producers in the field. Regarding the collaboration, the United States and China present a close connection. The scientific community is focused on the following topics: apoptosis, breast cancer, oxidative stress, chemotherapy, and nuclear factor-Kappa-B (NF-Kappa-B).
The present article shows potentially important information that allows understanding of the past, present, and future of research in integrative and complementary oncology. It is a useful evidence-based framework on which to base future research actions and academic directions.
全球范围内,癌症的发病率呈上升趋势。然而,在过去的 20 年中,癌症死亡率有所下降。因此,三分之一的癌症患者是补充和替代疗法的使用者,他们在寻找其他类型的干预措施。本研究的主要目的是了解综合和补充肿瘤学领域的研究现状。分析了三个不同方面:生产趋势、国家合作和主要研究课题。
该数据集来自 1976 年至 2017 年 Web of Science 数据库的综合与补充医学类别索引文件。使用 VOSviewer 和 SciMAT 软件进行文献计量分析。
《民族药理学杂志》、中国医科大学和中华人民共和国是该领域的主要生产者。就合作而言,美国和中国关系密切。科学界主要关注以下课题:细胞凋亡、乳腺癌、氧化应激、化疗和核因子-Kappa-B(NF-Kappa-B)。
本文提供了有关综合和补充肿瘤学研究的过去、现在和未来的潜在重要信息。它为未来的研究行动和学术方向提供了一个有用的循证框架。